Welcome and introduction (ID 1300)
Immune checkpoint molecules: key players in the pathogenesis of HCC (ID 1301)
Optimising the immune response: exploring high-dose priming with anti-CTLA-4 therapy in unresectable HCC (ID 1302)
Recent advances in the treatment of unresectable HCC (ID 1303)
Clinical experience in unresectable HCC (ID 1304)